% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Becker:143926,
      author       = {N. Becker$^*$ and E. Motsch$^*$ and A. Trotter$^*$ and C.
                      P. Heussel and H. Dienemann and P. A. Schnabel and H.-U.
                      Kauczor and S. González Maldonado$^*$ and A. B. Miller and
                      R. Kaaks$^*$ and S. Delorme$^*$},
      title        = {{L}ung cancer mortality reduction by {LDCT} screening -
                      results from the randomised {G}erman {LUSI} trial.},
      journal      = {International journal of cancer},
      volume       = {146},
      number       = {6},
      issn         = {1097-0215},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2019-01484},
      pages        = {1503-1513},
      year         = {2020},
      note         = {2020 Mar 15;146(6):1503-1513 #EA:C020#LA:E010#},
      abstract     = {In 2011, the US National Lung Cancer Screening Trial (NLST)
                      reported a $20\%$ reduction of lung cancer mortality after
                      regular screening by low-dose computed tomography (LDCT), as
                      compared to X-ray screening. The introduction of lung cancer
                      screening programs in Europe awaits confirmation of these
                      first findings from European trials that started in parallel
                      with the NLST. The German Lung cancer Screening Intervention
                      ('LUSI') is a randomized trial among 4,052 long-term
                      smokers, 50-69 years of age, recruited from the general
                      population, comparing 5 annual rounds of LDCT screening
                      (screening arm; n=2,029 participants) with a control arm
                      (n=2,023) followed by annual postal questionnaire inquiries.
                      Data on lung cancer incidence and mortality and vital status
                      were collected from hospitals or office-based physicians,
                      cancer registries, population registers and health offices.
                      Over an average observation time of 8.8 years after
                      randomization, the hazard ratio for lung cancer mortality
                      was 0.74 $[95\%CI:$ 0.46 - 1.19; p=0.21] among men and women
                      combined. Modelling by sex, however showed a statistically
                      significant reduction in lung cancer mortality among women
                      (HR=0.31 $[95\%CI:$ 0.10 - 0.96], p=0.04), but not among men
                      (HR=0.94 $[95\%CI:$ 0.54 - 1.61], p=0.81) screened by LDCT
                      (pheterogeneity = 0.09). Findings from LUSI are in line with
                      those from other trials, including NLST, that suggest a
                      stronger reduction of lung cancer mortality after LDCT
                      screening among women as compared to men. This heterogeneity
                      could be the result of different relative counts of lung
                      tumor sub-types occurring in men and women. This article is
                      protected by copyright. All rights reserved.},
      cin          = {C020 / E010},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331 / I:(DE-He78)E010-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31162856},
      doi          = {10.1002/ijc.32486},
      url          = {https://inrepo02.dkfz.de/record/143926},
}